Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 3;78(10):2591-2596.
doi: 10.1093/jac/dkad278.

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

Alejandro Gonzalez-Serna  1   2   3   4   5 , Anaïs Corma-Gomez  1   3   4   5 , Francisco Tellez  5   6 , Diana Corona-Mata  5   7 , María Jose Rios-Villegas  5   8 , Dolores Merino  5   9 , Carlos Galera  5   10 , Antonio Ramon Collado-Romacho  5   11 , Ignacio De Los Santos  5   12 , Josep Cucurull  5   13 , Marta Santos  1   3   4   5 , Sofía García-Martín  5   14 , Antonio Rivero  5   7 , Luis Miguel Real  1   3   4   5   15 , Juan Macias  1   3   4   5   16
Affiliations

Response to glecaprevir/pibrentasvir in HIV/HCV-coinfected patients in clinical practice

Alejandro Gonzalez-Serna et al. J Antimicrob Chemother. .

Abstract

Objectives: HIV infection has been associated with lower rates of sustained viral response (SVR) with direct-acting antivirals (DAAs). There are few data on glecaprevir/pibrentasvir (G/P) in HIV/HCV coinfection outside clinical trials.

Methods: The HEPAVIR-DAA cohort, which recruits HIV/HCV-coinfected patients (NCT02057003) and the GEHEP-MONO cohort (NCT02333292), including HCV-monoinfected individuals, are two concurrent ongoing multicentre cohorts of patients receiving anti-HCV treatment. Patients starting G/P included in those cohorts were analysed. Overall SVR (ITT), discontinuations due to adverse effects, and dropouts were evaluated and compared between both cohorts.

Results: Of the 644 patients who started G/P with evaluable SVR, 132 were HIV/HCV coinfected. Overall SVR rates were 487/512 (95.1%) in HCV-monoinfected patients versus 126/132 (95.5%) in HIV/HCV-coinfected patients (P = 1.000). One patient (0.8%) relapsed, and another (0.8%) discontinued treatment due to side effects. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected versus HCV-monoinfected patients. The main reason for not reaching SVR among HIV/HCV-coinfected patients was premature dropout linked to active drug use.

Conclusions: G/P in HIV/HCV coinfection was highly effective and tolerable in clinical practice. SVR to 8 or 12 weeks of treatment with G/P was similar in HIV/HCV-coinfected compared with HCV-monoinfected patients but active drug use is still a barrier to reach HCV microelimination.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart of patients.
See this image and copyright information in PMC

References

    1. Forns X, Lee SS, Valdes J et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17: 1062–8. 10.1016/S1473-3099(17)30496-6 - DOI - PubMed
    1. Wyles D, Poordad F, Wang S, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2018; 67: 514–23. 10.1002/hep.29541 - DOI - PMC - PubMed
    1. Foster GR, Asselah T, Kopecky-Bromberg S et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PloS One 2019; 14: e0208506. 10.1371/journal.pone.0208506 - DOI - PMC - PubMed
    1. Gonzalez-Serna A, Macias J, Corma-Gomez A et al. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use. J Infect 2022; 85: 322–6. 10.1016/j.jinf.2022.06.005 - DOI - PubMed
    1. Zuckerman E, Gutierrez JA, Dylla DE et al. Eight weeks treatment with glecaprevir/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2020; 18: 2544–53.e6. 10.1016/j.cgh.2020.06.044 - DOI - PubMed

Publication types

MeSH terms

Associated data